ChartRow logo
Share this page
ARQT
$28.82-0.96%
as of close, Oct 16, 2026
☾ AH $28.82 -0.96%
PeersMRNALLYMDTUNHJNJTMO

Arcutis Biotherapeutics Inc. trailing returns

How Arcutis Biotherapeutics Inc. (ARQT) has performed over the last day, week, month and year, over 5 years, and since inception, through October 16, 2026 — price return and dividends side by side, with the worst drop inside each window.

Trailing returns by period#

To 2026-10-16. Price return + dividends = total return. Per year (CAGR) for windows of a year or more, with the cumulative total return beneath. Worst drop: the deepest fall in the price from a high inside the window, and when it bottomed.

PeriodPriceDivsTotalWorst drop
1 day-1.0%+0.0%-1.0%—
5 days+8.4%+0.0%+8.4%-1.8%Oct 13
1 month+10.3%+0.0%+10.3%-13.9%Oct 6
YTD-0.8%+0.0%-0.8%-35.4%May 19
1 year+37.8%+0.0%+37.8%-37.5%May 2026
5 years+5.3%+0.0%+5.3%+29.4%-93.2%Nov 2023
Since inception (2020)+4.2%+0.0%+4.2%+32.2%-95.0%Nov 2023

Growth of ARQT#

Actual level with dividends reinvested (solid); dashed lines are each window's constant-rate path from start to today.

  • 5 years+5.3%/year · +29.4%

Methodology#

Trailing returns measure from the closest close about N years before the latest close (2026-10-16). Cumulative return is the total change over the window; annualized return is the compound annual growth rate (CAGR), shown for windows of a year or more. Price return is the change in ARQT's closing price; total return reinvests dividends (from its split- and dividend-adjusted closes); the dividends column is the difference between the two. The worst drop is the largest fall in the closing price from a high to a later low inside the window, the way a drawdown is usually quoted. See the year-by-year returns for the calendar breakdown. Past performance does not predict future returns; not investment advice.

FAQ#

What is Arcutis Biotherapeutics Inc.'s return since inception?
Since 2020, Arcutis Biotherapeutics Inc. (ARQT) has compounded at about +4.2% a year — +32.2% in total.

More on Arcutis Biotherapeutics Inc.